Outlook Therapeutics Q3 2024 Earnings Report $1.44 +0.05 (+3.60%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Outlook Therapeutics EPS ResultsActual EPS-$0.83Consensus EPS -$1.06Beat/MissBeat by +$0.23One Year Ago EPSN/AOutlook Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOutlook Therapeutics Announcement DetailsQuarterQ3 2024Date8/14/2024TimeN/AConference Call ResourcesOTLK Earnings History We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Outlook Therapeutics Earnings HeadlinesATX Ahead: 2025 Economic Outlook event coming in JanuaryDecember 18 at 4:06 PM | bizjournals.comOutlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial LaunchDecember 13, 2024 | marketwatch.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.December 21, 2024 | Crypto Swap Profits (Ad)Outlook Therapeutics® Streamlines OperationsDecember 13, 2024 | globenewswire.comBTIG Reaffirms Their Buy Rating on Outlook Therapeutics (OTLK)December 11, 2024 | markets.businessinsider.comOutlook Therapeutics announces NICE recommendation of LYTENAVADecember 4, 2024 | markets.businessinsider.comSee More Outlook Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Outlook Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Outlook Therapeutics and other key companies, straight to your email. Email Address About Outlook TherapeuticsOutlook Therapeutics (NASDAQ:OTLK), operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.View Outlook Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
